Drug Class Description
Nucleoside reverse transcriptase inhibitors (NRTIs).
Generic Name
Didanosine
Drug Description
White chewable/dispersible tablets marked with name and strength.
Presentation
Tablets, didanosine 25mg , 100mg , 150mg , 200mg .
Indications
As part of a combination therapy for antiviral treatment of HIV infected patients.
Adult Dosage
Under 60 kg, initially 250mg daily in one or two divided doses
Over 60 kg, initially 400mg daily in one or two divided doses.Each dose must be given as minimum 2 tablets to provide sufficient antacid and be taken chewed or dispersed in at least 30mL water (diluted with clear apple juice if desired) at least 30 minutes before a meal.
Child Dosage
Under 3 months, not recommended; over 3 months, initially 240 mg/ m2 daily (or 180 mg/m 2 daily in combination with zidovudine) in one or two divided doses.
Contra Indications
Hypersensitivity to didanosine or
Special Precautions
Renal or hepatic impairment. Pancreatitis; monitor serum amylase levels before and during therapy. Monitor uric acid, triglyceride and liver enzymes. Check for peripheral neuropathy. Phenylketonuria. Monitor retinal changes in children. Lactic acidosis. Pregnancy, lactation.
Interactions
Tetracyclines. Drugs that affect or are affected by gastric pH (eg, ketoconazole and itraconazole) should be given at least two hours before Videx. Ganciclovir. Drugs causing pancreatitis or peripheral neuropathy.
Adverse Reactions
Pancreatitis, peripheral neuropathy. Abnormal liver function tests; rarely liver failure. Diarrhoea, nausea/ vomiting, allergic reactions, diabetes mellitus, dry mouth, asthenia, headache, elevated uric acid levels. Rarely retinal or optic nerve changes. Blood dyscrasias. Lactic acidosis.
Manufacturer
Bristol-Myers Squibb
Drug Availability
(POM)
Updated
26 March 2009 
